Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) Revenue (2016 - 2025)

Historic Revenue for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to $756217.0.

  • China Pharma Holdings' Revenue fell 3126.25% to $756217.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.1 million, marking a year-over-year decrease of 2691.54%. This contributed to the annual value of $4.5 million for FY2024, which is 3540.53% down from last year.
  • Per China Pharma Holdings' latest filing, its Revenue stood at $756217.0 for Q3 2025, which was down 3126.25% from $1.0 million recorded in Q2 2025.
  • Over the past 5 years, China Pharma Holdings' Revenue peaked at $2.9 million during Q4 2022, and registered a low of $756217.0 during Q3 2025.
  • Over the past 5 years, China Pharma Holdings' median Revenue value was $1.6 million (recorded in 2022), while the average stood at $1.7 million.
  • In the last 5 years, China Pharma Holdings' Revenue soared by 3369.79% in 2021 and then plummeted by 4724.83% in 2024.
  • China Pharma Holdings' Revenue (Quarter) stood at $2.9 million in 2021, then rose by 1.09% to $2.9 million in 2022, then fell by 26.41% to $2.1 million in 2023, then tumbled by 47.25% to $1.1 million in 2024, then tumbled by 33.31% to $756217.0 in 2025.
  • Its Revenue stands at $756217.0 for Q3 2025, versus $1.0 million for Q2 2025 and $1.1 million for Q1 2025.